β-endorphin and ACTH are Dissociated After Self-Injury in Adults with Developmental Disabilities

American Journal on Mental Retardation

Volumn 108, Issue 6, 2003, Pages 414-424+438

  Sandman, Curt A ^a,b   Touchette, Paul ^a   Lenjavi, Mohammed ^a   Marion, Sarah ^a   Chicz DeMet, Aleksandra ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Box 7 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ENDORPHIN; CORTICOTROPIN; NALTREXONE;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOMUTILATION; BEHAVIOR DISORDER; CLINICAL ARTICLE; CONTROLLED STUDY; DEVELOPMENTAL DISORDER; DISEASE ASSOCIATION; DISSOCIATION; DOSE RESPONSE; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; TREATMENT OUTCOME; TREATMENT PLANNING;

ADOLESCENT; ADRENOCORTICOTROPIC HORMONE; ADULT; AGED; BETA-ENDORPHIN; CIRCADIAN RHYTHM; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; MIDDLE AGED; NALOXONE; NARCOTIC ANTAGONISTS; PITUITARY-ADRENAL SYSTEM; PRO-OPIOMELANOCORTIN; SELF-INJURIOUS BEHAVIOR;

EID: 10744220094     PISSN: 08958017     EISSN: None     Source Type: Journal    
DOI: 10.1352/0895-8017(2003)108<414:EAAADA>2.0.CO;2     Document Type: Article

References (61)

1. th ed., text rev.). Washington, DC: Author.
2. Barna, I., Koenig, J. I., & Davis, T. P. (1992). Effects of mediobasal hypothalamic lesion on immunoreactive ACTH/beta-endorphin levels in cerebrospinal fluid, in discrete brain regions, in plasma and in pituitary of the rat. Brain Research, 593, 69-76.
3. Beckwith, W., Sandman, C. A., Hothersall, D., & Kastin, A. J. (1976). The influence of neonatal injections of a-MSH on learning, memory and attention in rats. Physiology and Behavior, 18, 63-71.
4. Belluzzi, J. D., & Stein, L. (1977). Enkephaline may mediate euphoria and drive-reduction reward. Nature, 266, 556-558.
5. Bertagna, X. (1994). Proopiomelanocortin-derived peptides. Endocrinology and Metabolism Clinics of North America, 23, 85.
6. Bicknell, A. B., Savva, D., & Lowry, P. J. (1996). Pro-opiomelanocortin and adrenal function. Endocrine Research, 22, 385-393.
7. Boutillier, A. L., Monnier, D., Lorang, D., Lundblad, J. R., Roberts, J. L., & Loeffler, J. P. (1995). Corticotropin-releasing hormone stimulates propiomelanocortin transcription by cFos-dependent and -independent pathways: Characterization of an AP1 site in exon 1. Molecular Endocrinology, 9, 745-755.
8. Bouvard, M. P., Leboyer, M., Launay, J. M., Recasens, C., Plumet, M. H., Waller-Perotte, D., Tabuteau, F., Bondoux, D., Dugas, M., Lensing, P., & Panksepp, J. (1995). Low-dose naltrexone effects on plasma chemistries and clinical symptoms in autism: A double-blind, placebo-controlled study. Psychiatry Research, 58, 191-201.
9. Cazzullo, A. G., Musetti, M. C., Musetti, L., Bajo, S., Sacerdote, P., & Panerai, A. (1999). Beta-endorphin levels in peripheral blood mononuclear cells and long-term naltrexone treatment in autistic children. European Neuropsycholopharmacology: Journal of the European College of Neuropsychopharmacology, 9, 361-363.
10. Crain, S. M., & Shen, K. F. (1995). Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic cotreatment. Proceedings of the National Academy of Science of the United States of America, 92, 10540-10544.
11. Ernst, M., Devi, L., Silva, R. R., Gonzalez, M. N., Small, A. M., Malone, R. P., & Campbell, M. (1993). Plasma beta-endorphin levels, naltrexone, and haloperidol in autistic children. Psychopharmacology Bulletin, 29, 221-227.
12. Forman, L. J., Cavalieri, R., Estilow, S., & Tatarian, G. T. (1990). The elevation of immunoreactive B-endorphin in old male rats is related to alterations in dopamine and serotonin. Neurobiology of Aging, 11, 223-227.
13. Gallagher, T. F., Yoshida, K., Roffwarg, H. D., Fukushima, D. K., Weitzman, E. D., & Hellman, L. (1973). ACTH and cortisol secretory patterns in man. Journal of Clinical Endocrinology and Metabolism, 36, 1058-1068.
14. Guiffre, K. A., Udelsman, R., Listwak, S., & Chrousos, G. P. (1988). Effects of immune neutralization of corticotropin-releasing hormone, adrenocorticotropin, and B-endorphin in the surgically stressed rat. Endocrinology, 122, 306-310.
15. Guillemin, R., Vargo, T., Rossier, J., Minick, S., Ling, N., Rivier, C., Vale, W., & Bloom, F. (1977). Beta-endorphin and adrenocorticotropin are selected concomitantly by the pituitary gland. Science, 197, 1367-1369.
16. Hargreaves, K. M., Flores, C. M., Dionne, F. A., & Mueller, G. P. (1990). The role of the pituitary beta-endorphin in mediating corticotropin-releasing factor-induced antinociception. American Journal of Physiology, 258, 235-242.
17. Hendris, C. A. (1989). Naloxone-sensitive hyperalgesia induced by morphine and environment stimulation. Pharmacology, Biochemistry and Behavior, 32, 961-966.
18. Hendris, W. P., Isenhart, R. C., Taylor, D. V., & Sandman, C. A. (1991). ODAP: A stand alone program for observational data acquisition. Behavior Research Methods, Instruments and Computers: A Journal of the Psychonomic Society, 23, 66-71.
19. Holson, R. R., Scallet, A. C., Ali, S. F., Sullivan, P., & Gough, B. (1988). Adrenocortical, B-endorphin and behavioral responses to graded stressors in differentially reared rats. Physiology and Behavior, 42, 125-130.
20. Jackson, R. S., Creemers, J. W. M., Ohagi, S., Raffin-Sanson, M., Sanders, L., Montague, C. T., Hutton, J. C., & O'Rahilly, S. (1997). Obesity and impaired prohormone processing associated with mutations in the human prohormone conertase 1 gene. Nature Genetics, 16, 303-306.
21. Kjeor, A., Knigge, U., Bach, F. W., & Warberg, J. (1992). Histamine- and stress-induced secretion of ACTH and B-endorphin: Involvement of corticotropin-releasing hormone and vasopressin. Neuroendocrinology, 56, 419-428.
22. Knigge, U., Matzen, S., Bach, F., Bang, P., & Warberg, J. (1989). Involvement of histaminergic neurons in the stress-induced release of proopiomelanocortin-derived peptides in rats. Acta Endocrinologica (Copenhagen), 120, 533-539.
23. Krieger, D. T., Allen, W., Rizzo, F., & Krieger, H. P. (1971). Characterization of the normal temporal pattern of plasma corticosteroid levels. Journal of Clinical Endocrinology and Metabolism, 32, 266-284.
24. Krivoy, W. A., Kroeger, D. C., & Zimmerman, E. (1977). Neuropeptides: Influence of acute and chronic effects of opiates. Psychoneuroendocrinology, 21, 43-51.
25. Laatikainen, T., Virtanen, T., Kaaja, R., & Salminen-Lappalainen, K. (1991). Corticotropin releasing hormone in maternal and cord plasma in pre-eclampsia. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 39, 19-24.
26. Mains, R. E., & Eipper, B. A. (1999). Peptides. In G. J. Siegal, B. W. Agranoff, R. W. Albers, S. K. Fisher, & M. D. Uhler (Ed.), Basic neurochemistry: Molecular, cellular and medical aspects (6th ed., pp. 363-382). Philadelphia: Lippincott, Williams & Wilkins.
27. Naber, D., Cohen, R. M., Pickar, D., Kalin, N. H., Davis, G., Pert, C. B., & Bunney, W. E., Jr. (1981). Episodic secretion of opioid activity in human plasma and monkey CSF: Evidence for a diurnal rhythm. Life Sciences, 28, 931-935.
28. Nakao, K., Oki, S., Tanaka, I., Nakai, Y., & Imura, H. (1980). Concomitant secretion of Y-MSH with ACTH and beta-endorphin in humans. Journal of Clinical Endocrinology and Metabolism, 51, 1205-1207.
29. Noldus (1997). The Observer: System for collection and analysis of observational data. Noldus Information Technology, Wageningen, Holland.
30. Oltras, C. M., Mora, F., & Vives, F. (1987). B-endorphin and ACTH in plasma: Effects of physical and psychological stress. Life Sciences, 40, 1683-1686.
31. Panksepp, J., Herman, H., Conner, R., Bishop, P., & Scott, J. P. (1978). The biology of social attachments: Opiates alleviate separation distress. Biological Psychiatry, 13, 607-618.
32. Recher, H., Willis, G. L., Smit, G. C., & Copolov, D. L. (1988). B-endorphin, corticosterone, cholesterol and triglyceride concentrations in rat plasma after stress, cingulotomy or both. Pharmacology, Biochemistry and Behavior, 31, 75-79.
33. Reisine, T., & Pasternak, G. (1996). Opioid analgesics and antagonists. In J. G. Hardman, L. E. Limbird, P. B. Molinoff, R. W. Ruddon, & A. G. Gilman (Eds.), The pharmacological basis of therapeutics (pp. 521-556). New York: Mc-Graw-Hill.
34. Rosenblatt, M. I., & Dickerson, I. M. (1997). Endoproteolysis at tetrabasic amino acid sites in procalcitonin gene-related peptide by pituitary cell lines. Peptides, 18, 567-576.
35. Sandman, C. A. (1990/1991). The opiate hypothesis in autism and self-injury. Journal of Child and Adolescent Psychopharmacology, 1, 235-246.
36. Sandman, C. A., Alexander, W. D., & Kastin, A. J. (1973). Neuroendocrine influences on visual discrimination and reversal learning in the albino and hooded rat. Physiology & Behavior, 11, 613-617.
37. Sandman, C. A., Hetrick, W. P., Taylor, D. V., Barron, J. L., Touchette, P., Lott, I., Crinella, F., & Martinazzi, V. (1993). Naltrexone reduces self-injury and improves learning. Experimental and Clinical Psychopharmacology, 1, 242-258.
38. Sandman, C. A., Hetrick, W. P., Taylor, D. V., & Chicz-DeMet, A. (1997). Dissociation of POMC peptides after self-injury predicts responses to centrally acting opiate blockers. American Journal on Mental Retardation, 102, 182-199.
39. Sandman, C. A., Hetrick, W., Taylor, D., Marion, S., & Chicz-DeMet, A. (2000). Uncoupling of proopiomelanocortin (POMC) fragments is related to self-injury. Peptides, 21, 785-791.
40. Sandman, C. A., Hetrick, W. P., Taylor, D. V., Marion, S., Touchette, P., Barron, J. L., Martinazzi, V., Steinberg, R., & Crinella, F. M. (2000). Long-term effects of naltrexone on self-injurious behavior. American Journal of Mental Retardation, 105, 103-117.
41. Sandman, C. A., & Kastin, A. J. (1981). The influence of fragments of the LPH chain on learning, memory and attention in animals and man. Pharmacology and Therapeutics, 13, 39-60.
42. Sandman, C. A., & Kastin, A. J. (1990). Neuropeptide modulation of development and behavior: Implications for psychopathology. In S. Deutsch (Ed.), Application of basic neuroscience to child psychiatry (pp. 101-124). Washington, DC: Plenum.
43. Sandman, C. A., Miller, L. H., Kastin, A. J., & Schally, A. V. (1972). Neuroendocrine influence on attention and memory. Journal of Comparative Physiology and Psychology, 80, 54-58.
44. Sandman, C. A., Spence, M. A., & Smith, M. (1999). Proopiomelanocortin (POMC) disregulation and response to opiate blockers. Mental Retardation and Developmental Disabilities Research Review, 5, 314-321.
45. Sandman, C. A., Thompson, T., Barrett, R. P., Verhoeven, W. M. A., McCubbin, J. A., Schroeder, S. R., & Hetrick, W. P. (1998). Opiate blockers. In M. Aman & S. Reiss (Eds.), Consensus handbook on psychopharmacology (pp. 291-302). Unpublished handbook, Ohio State University, Nisonger Center.
46. Sandman, C.A., Touchette, P., Ly, J., Marion, S., & Bruinsma, Y. (2000). Computerized-assessment of treatment effects among individuals with developmental disabilities. In T. Thompson, D. Felce, & F. Symons (Eds.), Behavioral observations: Technology and applications in developmental disabilities (pp. 271-293). Baltimore: Brookes.
47. Sandman, C. A., Touchette, P., Marion, S., Lenjavi, M., & Chicz-DeMet, A. (2002). Disregulation of proopiomelanocortin and contagious maladaptive behavior. Regulatory Peptides, 108, 179-185
48. Sasaki, A., Shinkawa, O., Margioris, A. N., Liotta, A. S., Sato, S., Murakami, O., Go, M., Shimizu, Y., Hanew, K., & Yoshinaga, K. (1987). Immunoreactive corticotropin-releasing hormone in human plasma during pregnancy, labor, and delivery. Journal of Clinical Endocrinology and Metabolism, 64, 224-229.
49. Scifo, R., Cioni, M., Nicolosi, A., Batticane, N., Tirolo, C., Testa, N., Quattropani, M. C., Morale, M. C., Gallo, F., & Marchetti, B. (1996). Opioid-immune interactions in autism: Behavioural and immunological assessment during a double-blind treatment with naltrexone. Annali Dell'istituto Superiore Di Sanita, 32, 351-359.
50. Seidah, N. G., & Chretien, M. (1992). Proprotein and prohormone convertases of the subtilisin family. Trends in Endocrinology and Metabolism, 3, 133-140.
51. Seidah, N. G., Mattei, M. G., Gaspar, L., Benjannet, S., Mbikay, M., & Chretian, M. (1991). Chromosomal assignments of the genes for neuroendocrine convertase PC1 (NEC1) to human 5q15-21, neuroendocrine convertase PC2 (NEC2) to human 20p11.1-11.2, and furin (mouse 7[D1-E2] region). Genomics, 11, 103-107.
52. Shen, K., & Crain, S. M. (1992). Chronic selective activation of excitatory opioid receptor functions in sensory neurons results in opioid "dependence" without tolerance. Brain Research, 597, 74-83.
53. Shutt, D. A., Smith, A. I., Wallace, C. A., Connell, R., & Fell, L. R. (1988). Effect of myiasis and acute restraint stress on plasma levels of immunoreactive B-endorphin, adrenocorticotrophin (ACTH) and cortisol in sheep. Australian Journal of Biological Sciences, 41, 297-301.
54. Strand, F. L. (1999). Neuropeptides: Regulators of physiological processes. Cambridge: MIT Press.
55. Symons, F. J., Tapp, J., Wulfsberg, A., Sutton, K. A., Heeth, W. L., & Bodfish, J. W. (2001). Sequential analysis of the effects of naltrexone on the environmental mediation of self-injurious behavior. Experimental and Clinical Psychopharmacology, 9, 269-276.
56. Szekely, J., Miglecz, E., Dunai-Kovacs, Z., Tarnawa, I., Ronai, A. Z., Graf, L., & Bajusz, S. (1979). Attenuation of morphine tolerance and dependence by α-melanocyte stimulating hormone. Life Sciences, 24, 1931-1938.
57. Tanaka, K., Nicholson, W. E., & Orth, D. N. (1978). Diurnal rhythm and disappearance half-time of endogenous plasma immunoreactive beta-MSH (LPH) and ACTH in man. Journal of Clinical Endocrinology and Metabolism, 46, 883-890.
58. Thompson, T., Hackenberg, T., Cerutti, D., Baker, D., & Axtell, S. (1994). Opioid antagonist effects on self-injury in adults with mental retardation: Response form and location as determinants of mediation effect. American Journal on Mental Retardation, 99, 85-102.
59. White, T., & Schultz, S. K. (2000). Naltrexone treatment for a 3-year-old boy with self-injurious behavior. American Journal of Psychiatry, 157, 1574.
60. Willemsen-Swinkels, S. H. N., Buitelaar, J. K., van Berchelaer-Onnes, I., & van Engeland, H. (1999). Brief report: Six months continuation treatment in naltrexone-responsive children with autism: An open-label case-control design. Journal of Autism and Developmental Disabilities, 29, 167-169.
61. Zheng, M., Streck, R. D., Scott, R. E. M., Seidah, N. J., & Pintar, J. E. (1994). The developmental expression in rat of proteases furin, PC1, PC2, and carboxypeptidase E: Implications for early maturation of proteolytic processing capacity. Journal of Neuroscience, 14, 4656-4673.